Skip to main content

Table 4 Correlation of ZEB1-AS1(T1-4) and ZEB1-AS1(T5,6) expression with clinicopathological features in luminal BC patients

From: Expression profiles and functional prediction of long non-coding RNAs LINC01133, ZEB1-AS1 and ABHD11-AS1 in the luminal subtype of breast cancer

Characteristics No. of cases (total: 79) ZEB1-AS1(T1-4) expression level ZEB1-AS1(T5,6) expression level
Low
N (%)
High
N (%)
P-value Low
N (%)
High
N (%)
P-value
Age at diagnosis (2 missing, n = 77)
 ≤ 40 20 12 (30.8%) 8 (21.1%) 0.33 12 (31.6%) 8 (20.5%) 0.26
 > 40 57 27 (69.2%) 30 (78.9%)   26 (68.4%) 31 (79.5%)  
Tumor size (1 missing, n = 78)
 < 2 cm 23 11 (28.9%) 12 (30.0%) 0.15 10 (25.7%) 13 (33.3%) 0.25
 2–5 cm 41 17 (44.8%) 24 (60.0%)   24 (61.5%) 17 (43.6%)  
 > 5 cm 14 10 (26.3%) 4 (10.0%)   5 (12.8%) 9 (23.1%)  
Tumor subtype (n = 79)
 Luminal A 65 36 (90.0%) 29 (74.4%) 0.07 32 (80.0%) 33 (84.6%) 0.59
 Luminal B 14 4 (10.0%) 10 (25.6%)   8 (20.0%) 6 (15.4%)  
Grade (n = 79)
 1 11 6 (15.0%) 5 (12.8%) 0.80 6 (15.0%) 5 (12.8%) 0.80
 2 54 28 (70.0%) 26 (66.7%)   26 (65%) 28 (71.8%)  
 3 14 6 (15.0%) 8 (20.5%)   8 (20.0%) 6 (15.4%)  
Stage (2 missing, n = 77)
 I 6 3 (7.9%) 3 (7.7%) 0.94 3 (7.7%) 3 (7.9%) 0.82
 II 42 20 (52.6%) 22 (56.4%)   20 (51.3%) 22 (57.9%)  
 III 29 15 (39.5%) 14 (35.9%)   16 (41.0%) 13 (34.2%)  
Pathology of tumors (7 missing, n = 72)
 DCIS 3 1 (2.6%) 2 (5.9%) 0.20 1 (2.8%) 2 (5.6%) 0.32
 LCIS 3 3 (7.9%) 0 (0.0%)   0 (0.0%) 3 (8.3%)  
 IDC 57 29 (76.3%) 28 (82.4%)   30 (83.3%) 27 (75.0%)  
 ILC 4 1 (2.6%) 3 (8.8%)   3 (8.3%) 1 (2.8%)  
 Others 5 4 (10.6%) 1 (2.9%)   2 (5.6%) 3 (8.3%)  
Progesterone receptor (n = 79)
 Negative 10 4 (10.0%) 6 (15.4%) 0.47 4 (10.0%) 6 (15.4%) 0.47
 Positive 69 36 (90.0%) 33 (84.6%)   36 (90.0%) 33 (84.6%)  
Estrogen receptor (n = 79)
 Negative 0 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Positive 79 40 (100.0%) 39 (100.0%)   40 (100.0%) 39 (100.0%)  
HER2 (n = 79)
 Negative 70 37 (92.5%) 33 (84.6%) 0.69 36 (90.0%) 34 (87.2%) 0.69
 Positive 9 3 (7.5%) 6 (15.4%)   4 (10.0%) 5 (12.8%)  
  1. Stage grouping is based on American Joint Committee on Cancer (AJCC). Estrogen receptor (ER), progesterone receptor (PR), and Her2/neu classification is based on IHC results. The positive cut-off point is determined according to IHC guideline of American Society of Clinical Oncology (ASCO)
  2. DCIS Ductal Carcinoma in Situ; LCIS Lobular Carcinoma in Situ, IDC Invasive Ductal Carcinoma, ILC Invasive Lobular Carcinoma